scholarly journals Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine (Pcv13) in Public and Private System Versus Ppsv23 and No Vaccination in Older Adults

2015 ◽  
Vol 18 (7) ◽  
pp. A839 ◽  
Author(s):  
CN Ferreira ◽  
CF Santana ◽  
C Rufino
Keyword(s):  
Public Health ◽  
Older Adults ◽  
Economic Impact ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Public And Private ◽  
System Versus

Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50years

Vaccine ◽  
2012 ◽  
Vol 30 (36) ◽  
pp. 5437-5444 ◽  
Author(s):  
Derek Weycker ◽  
Reiko Sato ◽  
David Strutton ◽  
John Edelsberg ◽  
Mark Atwood ◽  
...  
Keyword(s):  
Public Health ◽  
Economic Impact ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States

Vaccine ◽  
2010 ◽  
Vol 28 (48) ◽  
pp. 7634-7643 ◽  
Author(s):  
Jaime L. Rubin ◽  
Lisa J. McGarry ◽  
David R. Strutton ◽  
Keith P. Klugman ◽  
Stephen I. Pelton ◽  
...  
Keyword(s):  
Public Health ◽  
United States ◽  
Economic Impact ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
The United States

scholarly journals Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy

Pathogens ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 76
Author(s):  
Filippo Ansaldi ◽  
Sarah Pugh ◽  
Daniela Amicizia ◽  
Roberto Di Virgilio ◽  
Cecilia Trucchi ◽  
...  
Keyword(s):  
Public Health ◽  
Economic Impact ◽  
Conjugate Vaccine ◽  
Invasive Pneumococcal Disease ◽  
Pneumococcal Conjugate Vaccine ◽  
Time Horizon ◽  
Pneumococcal Disease ◽  
Cost Effective ◽  
The Elderly ◽  
Sensitivity Analyses

Background: Invasive and non-invasive pneumococcal diseases are significant health and economic burdens, especially in children and the elderly. Italy included the 7-valent (PCV7) and 13-valent pneumococcal conjugate vaccine (PCV13) in the National Immunization Program in 2007 and 2010, respectively, allowing a dramatic reduction in the burden of pneumococcal disease. In the era of budget constraints, decision-makers may consider switching from the higher-valent, more costly PCV13, to the lower-cost PCV10. This study estimated the potential public health and economic impact of changing vaccine programs from PCV13 to PCV10 in Italy. Methods: A decision-analytic forecasting model estimated the impact of PCV programs. Real-world surveillance data were used to forecast serotype distribution and disease incidence among children and the elderly over a specified 5-year time horizon. Costs and outcomes included estimates of cases and deaths avoided, quality-adjusted life years (QALYs) gained, and total costs from a payer perspective, discounted at an assumed rate of 3.0%, and robustness validated through several scenarios and sensitivity analyses. Results: A switch from PCV13 to PCV10 would increase invasive pneumococcal disease (IPD) cases by 59.3% (4317 cases) over a 5-year horizon, primarily due to serotypes 3 and 19A. Pneumonia increased by 8.3% and acute otitis media (AOM) by 96.1%. Maintaining a PCV13 program would prevent a total incremental 531,435 disease cases (1.02M over a 10-year time horizon) and 641 deaths due to invasive pneumococcal disease (IPD), with €23,642 per QALY gained over 5 years versus PCV10. One-way and probabilistic sensitivity analyses showed that a PCV13-based program remained cost-effective in 99.7% of the simulations in Italy as parameters varied within their plausible range; percent vaccinated had the most impact. Conclusions: Maintaining the PCV13 strategy would provide substantial public health and economic benefits in Italy and is cost-effective. Switching from PCV13 to PCV10 would increase the incidence of pneumococcal disease primarily linked to re-emergence of serotypes 3 and 19A.

scholarly journals Changes in Pneumonia Incidence and Infant Mortality 5 Years Following Introduction of the 13-valent Pneumococcal Conjugate Vaccine in a “3+0” Schedule in Nicaragua

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S67-S68
Author(s):  
Sylvia Becker-Dreps ◽  
Bryan Blette ◽  
Rafaela Briceno ◽  
Jorge Aleman ◽  
Michael G Hudgens ◽  
...  
Keyword(s):  
Public Health ◽  
Infant Mortality ◽  
Bacterial Meningitis ◽  
Health Facility ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Public Health Intervention ◽  
Vital Statistics ◽  
Health Facilities ◽  
One Year

Abstract Background Streptococcus pneumoniae causes an estimated 826,000 deaths of children in the world each year and many health facility visits. To reduce the burden of pneumococcal disease, many nations have added pneumococcal conjugate vaccines to their national immunization schedules. Nicaragua was the first country eligible for funding from the GAVI Alliance to introduce the 13-valent pneumococcal conjugate vaccine (PCV13), provided to infants at 2, 4, and 6 months of age. The goal of this study was to evaluate the population impact of the first five years of the program. Methods Numbers of visits for pneumonia, pneumonia-related deaths, bacterial meningitis, and infant deaths between 2008 and 2015 were collected from all 107 public health facilities in León Department. Vital statistics data provided additional counts of pneumonia-related deaths that occurred outside health facilities. Adjusted incidence rates and incidence rate ratios (IRRa) in the vaccine (2011–2015) and pre-vaccine periods (2008–2010) were estimated using official population estimates as exposure time. Results The IRRa for pneumonia hospitalizations was 0.70 (95% confidence interval [CI]: 0.66, 0.75) for infants, and 0.92 (95% CI: 0.85, 0.99) for one year olds. The IRRa for post-neonatal infant mortality was 0.56 (95% CI: 0.41, 0.77). In the population as a whole, ambulatory visits and hospitalizations for pneumonia, as well as pneumonia-related mortality and rates of bacterial meningitis were lower in the vaccine period. Conclusion Five years following program introduction, reductions were observed in health facility visits for pneumonia in immunized age groups and infant mortality, which would be hard to achieve with any other single public health intervention. Future study is warranted to understand whether the lack of a booster dose (e.g.,, at 12 months) may be responsible for the small reductions in pneumonia hospitalizations observed in one year-olds as compared with infants. Disclosures S. Becker-Dreps, Pfizer: Consultant and Grant Investigator, Consulting fee and Research grant; D. J. Weber, Pfizer: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium

Sign in / Sign up

Export Citation Format

Share Document